SCHEMBL10188164

SCHEMBL10188164

CCNc1cc(N)ncn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.49
CDK5 Q00535 2/20 0.41
CDK1 P06493 1/20 0.41
CCNB1 P14635 1/20 0.41
CCNA2 P20248 1/20 0.41
CCNE1 P24864 1/20 0.41
CDK2 P24941 1/20 0.41
CDK5R1 Q15078 1/20 0.41
SCN9A Q15858 1/20 0.39
KDR P35968 1/20 0.39
NOS3 P29474 2/20 0.38
NOS1 P29475 2/20 0.38
NOS2 P35228 2/20 0.38
DNM2 P50570 2/20 0.37
CA2 P00918 1/20 0.36
CHKA P35790 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
AURKA O14965 1/20 0.36
HRH4 Q9H3N8 1/20 0.36
ADRA2A P08913 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17210140 0.84 EGFR (0.56) EGFRDNM2L3MBTL1HRH4ADRA2A
SCHEMBL10187338 0.84 DNM2 (0.45) EGFRCDK5CDK1CCNB1CCNA2
SCHEMBL18636563 0.81 DNM2 (0.54) CDK5CDK1CCNB1CCNA2CCNE1
SCHEMBL17103026 0.80 DNM2 (0.60) CDK1CCNB1CDK2DNM2AURKA
SCHEMBL10187332 0.79 HRH4 (0.56) CDK5CDK1CCNB1CCNA2CCNE1
SCHEMBL15114903 0.77 EGFR (0.46) EGFRDNM2L3MBTL1HRH4CLK4
SCHEMBL29402899 0.76 EGFR (0.51) EGFRCDK5CDK1CCNB1CCNA2
SCHEMBL807297 0.76 EGFR (0.51) EGFRCDK5CDK1CCNB1CCNA2
SCHEMBL23025208 0.76 KDM4E (0.47) CDK5CDK1CCNB1CCNA2CCNE1
SCHEMBL18636555 0.76 HRH4 (0.54) EGFRCDK5CDK1CCNB1CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109030156-B Dyeing liquid for flow analysis 武汉百合龙腾生物科技有限责任公司 2021-03-16 CN disclosed
WO-2012001107-A1 PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-01-05 WO disclosed